Benzinga | Jul 13, 2020 07:44AM EDT

Cowen & Co. Initiates Coverage On Aimmune Therapeutics with Outperform Rating, Announces Price Target of $35

Cowen & Co. analyst Boris Peaker initiates coverage on Aimmune Therapeutics (NASDAQ:AIMT) with a Outperform rating and announces Price Target of $35.